247 related articles for article (PubMed ID: 34359755)
21.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
23. A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.
Heong V; Tan TZ; Miwa M; Ye J; Lim D; Herrington CS; Iida Y; Yano M; Yasuda M; Ngoi NY; Wong SJ; Okamoto A; Gourley C; Hasegawa K; Tan DS; Huang RY
J Pathol; 2021 Nov; 255(3):285-295. PubMed ID: 34322886
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Yano M; Katoh T; Miyazawa M; Miyazawa M; Ogane N; Miwa M; Hasegawa K; Narahara H; Yasuda M
Sci Rep; 2019 Feb; 9(1):2397. PubMed ID: 30787326
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
Long X; Lu H; Cai MC; Zang J; Zhang Z; Wu J; Liu X; Cheng L; Cheng J; Cheung LWT; Shen Z; Zhou Y; Di W; Zhuang G; Yin X
Br J Cancer; 2023 Jun; 128(11):2054-2062. PubMed ID: 36997661
[TBL] [Abstract][Full Text] [Related]
26. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Zhou W; Liu H; Yuan Z; Zundell J; Towers M; Lin J; Lombardi S; Nie H; Murphy B; Yang T; Wang C; Liao L; Goldman AR; Kannan T; Kossenkov AV; Drapkin R; Montaner LJ; Claiborne DT; Zhang N; Wu S; Zhang R
Cancer Cell; 2023 Apr; 41(4):740-756.e10. PubMed ID: 36963401
[TBL] [Abstract][Full Text] [Related]
27. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
29. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
[TBL] [Abstract][Full Text] [Related]
30. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
[TBL] [Abstract][Full Text] [Related]
31. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Lheureux S; Tinker A; Clarke B; Ghatage P; Welch S; Weberpals JI; Dhani NC; Butler MO; Tonkin K; Tan Q; Tan DSP; Brooks K; Ramsahai J; Wang L; Pham NA; Shaw PA; Tsao MS; Garg S; Stockley T; Oza AM
Clin Cancer Res; 2018 Dec; 24(24):6168-6174. PubMed ID: 30108107
[TBL] [Abstract][Full Text] [Related]
32. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells.
Kawabata A; Hayashi T; Akasu-Nagayoshi Y; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T
Curr Issues Mol Biol; 2022 Apr; 44(4):1587-1596. PubMed ID: 35723366
[TBL] [Abstract][Full Text] [Related]
34. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.
Wu S; Fukumoto T; Lin J; Nacarelli T; Wang Y; Ong D; Liu H; Fatkhutdinov N; Zundell JA; Karakashev S; Zhou W; Schwartz LE; Tang HY; Drapkin R; Liu Q; Huntsman DG; Kossenkov AV; Speicher DW; Schug ZT; Van Dang C; Zhang R
Nat Cancer; 2021 Feb; 2(2):189-200. PubMed ID: 34085048
[TBL] [Abstract][Full Text] [Related]
35. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract][Full Text] [Related]
36. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.
Fukumoto T; Fatkhutdinov N; Zundell JA; Tcyganov EN; Nacarelli T; Karakashev S; Wu S; Liu Q; Gabrilovich DI; Zhang R
Cancer Res; 2019 Nov; 79(21):5482-5489. PubMed ID: 31311810
[No Abstract] [Full Text] [Related]
37. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
[TBL] [Abstract][Full Text] [Related]
38. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
39. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
40. Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling.
Chandler RL; Raab JR; Vernon M; Magnuson T; Schisler JC
Genom Data; 2015 Sep; 5():329-32. PubMed ID: 26484281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]